Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Return on Sales: 2018-2025

Historic Return on Sales for Aclaris Therapeutics (ACRS) over the last 8 years, with Sep 2025 value amounting to -9.22%.

  • Aclaris Therapeutics' Return on Sales fell 781.00% to -9.22% in Q3 2025 from the same period last year, while for Sep 2025 it was -9.22%, marking a year-over-year decrease of 781.00%. This contributed to the annual value of -7.05% for FY2024, which is 422.00% down from last year.
  • Per Aclaris Therapeutics' latest filing, its Return on Sales stood at -9.22% for Q3 2025, which was down 11.93% from -8.24% recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Return on Sales peaked at -1.41% during Q3 2024, and registered a low of -13.53% during Q2 2022.
  • In the last 3 years, Aclaris Therapeutics' Return on Sales had a median value of -3.58% in 2023 and averaged -4.85%.
  • Its Return on Sales has fluctuated over the past 5 years, first plummeted by 1,168bps in 2021, then soared by 1,025bps in 2022.
  • Over the past 5 years, Aclaris Therapeutics' Return on Sales (Quarterly) stood at -13.27% in 2021, then spiked by 1,025bps to -3.02% in 2022, then rose by 5bps to -2.97% in 2023, then slumped by 419bps to -7.16% in 2024, then slumped by 781bps to -9.22% in 2025.
  • Its last three reported values are -9.22% in Q3 2025, -8.24% for Q2 2025, and -7.48% during Q1 2025.